Eisai’s Tsukuba

Eisai’s Supplementary New Drug Application Submitted In Japan for Fycompa

As Monotherapy for Partial-Onset Seizures, Pediatric Indication for Partial-Onset Seizures, as Well as New Formulation Tokyo, February 03, 2019: Eisai Co., Ltd.…

6 years ago

Eisai’s New Drug Application for Perampanel Designated for Priority Review by China National Medical Products Administration

For Adjunctive Treatment of Partial Onset Seizures Tokyo, January 05, 2019: Eisai Co., Ltd. announced that its in-house discovered and…

6 years ago